Background

Dr. Michael R. Hanley, Ph.D., served as the Chief Executive Officer of Celtaxsys, Inc. since December 2, 2010 until September 9, 2013. Dr. Hanley served as Vice President of Discovery Research of Amylin Pharmaceuticals, Inc. since October 2003 and served as its Chief Scientific Officer. From 1997 to 2003, he served as a Senior Consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, ... Zymogenetics, Elan Pharmaceuticals, and Chiron. Dr. Hanley has more than 20 years of managerial experience in the international life science industry including drug discovery, product development, and production. From 1981 to 1997, he held faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis, where he was Professor of Biological Chemistry. During his academic career, Dr. Hanley conducted extensive research in cell Signaling, Molecular Biology of receptors, and peptide pharmacology. Dr. Hanley also set-up and directed research programs in privately-held start-ups, such as Chemocentryx, PsychoGenics, and Harvard-based Resolvyx Pharmaceuticals. He served as Chairman of the Board of Celtaxsys, Inc. since December 2, 2010 until September 2013 and its Director since 2007 until September 2013. He serves as a Director of Metabolic Solutions Development Company, Isogenica, and Pieris. Dr. Hanley serves as a Director of Psylin Neurosciences, Inc., and PsychoGenics, Inc. He serves as a Member of Scientific Advisory Board at Aileron Therapeutics, Inc. He serves as a Member of Advisory Board at Cyntellect Inc. He serves on advisory or review panels for the National Institutes of Health, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. He served as a Member of Scientific Advisory Board of Amylin Pharmaceuticals, Inc. since 1992. Dr. Hanley is widely published and has been an Editorial Advisor for numerous journals, including the Journal of Biological Chemistry and Molecular and Cellular Endocrinology. He holds a Bachelor's of Science degree in Biochemistry and a Ph.D. in Molecular Biology from the University of California, Berkeley.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.